Condition: ERCP
Intervention: Procedure: ERCP guided biopsy or brush cytology
Sponsor: emad mamdouh
Not yet recruiting - verified June 2017
Feeds
6816 items (6816 unread) in 74 feeds
Acinar Cell Carcinoma
(29 unread)
Acinic Cell Carcinoma
(30 unread)
Adenoid Cystic Carcinoma
(93 unread)
Adrenal Gland Cancer
(419 unread)
Ampulla Of Vater
(34 unread)
Anal Cancer
(522 unread)
Angiosarcoma
(118 unread)
Appendix Cancer
(78 unread)
Bile Duct Cancer
(740 unread)
Brain and CNS
(1307 unread)
Carcinoid
(154 unread)
Endocrine/Neuroendocrine
(890 unread)
Gall Bladder Cancer
(172 unread)
Hemangioendothelioma
(60 unread)
Hepatoblastoma
(64 unread)
Pancreas
(63 unread)
Phyllodes
(33 unread)
PMP and Mucinous Tumors
(30 unread)
Rhabdomyosarcoma
(151 unread)
Sarcoma
(1829 unread)
Trial - Cholangiocarcinoma (45 unread)
-
Periampullary Lesions Via ERCP in Assuit University Hospital
Posted: June 3rd, 2017, 10:00am EDT
-
A Trial of Percutaneous vs. Endoscopic Drainage of Suspected Klatskin Tumors
Posted: May 26th, 2017, 10:00am EDT
Conditions: Cholangiocarcinoma; Hilar Lymphadenopathy; Biliary Stricture
Interventions: Procedure: PTBD; Procedure: ERC
Sponsors: Medical University of South Carolina; Yale University; Virginia Commonwealth University; Vanderbilt University; Stony Brook University; University of Southern California; Case Western Reserve University; Medical College of Wisconsin; Dartmouth University; University of Florida; Northwestern University; Johns Hopkins University; Washington University School of Medicine; University of Michigan; Boston University; Ohio State University; Borland-Groover Clinic; Methodist Health System; St. Louis University; Fox Chase Cancer Center; Emory University; Cedars-Sinai Medical Center; Johns Hopkins Community Physicians
Not yet recruiting - verified February 2017 -
Open Label Immunotherapy Trial of Inoperable Pancreatic Cancer
Posted: May 18th, 2017, 10:00am EDT
Condition: Pancreatic Cancer Non-resectable
Intervention: Biological: V3-P
Sponsor: Immunitor LLC
Recruiting - verified May 2017 -
RFA for Malignant Biliary Obstruction
Posted: May 14th, 2017, 10:00am EDT
Conditions: Cholangiocarcinoma; Pancreas Cancer
Interventions: Procedure: Radiofrequency ablation; Procedure: Biliary stenting
Sponsor: Institute for Clinical and Experimental Medicine
Recruiting - verified May 2017 -
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Posted: May 5th, 2017, 10:00am EDT
Conditions: Advanced Hepatocellular Carcinoma (HCC); Cholangiocarcinoma; Esophageal Cancer; Nasopharyngeal Cancer; Serous Ovarian Cancer; Solid Tumor Malignancies With Documented FGF19/FGFR4 Alteration
Intervention: Drug: INCB062079
Sponsor: Incyte Corporation
Recruiting - verified June 2017 -
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
Posted: May 4th, 2017, 10:00am EDT
Conditions: Solid Tumor, Adult; Breast Cancer; Non Small Cell Lung Cancer; Prostate Cancer; Ovarian Cancer; Endometrial Cancer; Head and Neck Cancer; Cholangiocarcinoma
Intervention: Drug: CX-2009
Sponsor: CytomX Therapeutics
Recruiting - verified June 2017 -
Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or Colon Cancer
Posted: April 29th, 2017, 10:00am EDT
Conditions: Colon Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Pancreatic Carcinoma
Interventions: Procedure: Biospecimen Collection; Other: Laboratory Biomarker Analysis; Other: Laboratory Procedure
Sponsors: University of Southern California; National Cancer Institute (NCI)
Recruiting - verified April 2017 -
Diagnostic Accuracy of ERCP-guided Versus Cholangioscopy-guided Tissue Acquisition in Patients With Indeterminate Biliary Strictures Suspected to be Intrinsic - a Randomized Controlled Study
Posted: April 25th, 2017, 10:00am EDT
Conditions: Cholangiocarcinoma; Biliary Stricture
Interventions: Device: single operator cholangioscopy; Device: ERCP guided brushing and biopsy
Sponsors: Asian Institute of Gastroenterology, India; Prince of Wales Hospital, Shatin, Hong Kong; Evangelisches Krankenhaus Düsseldorf
Not yet recruiting - verified May 2017 -
Impact of Three-dimensional Visualization on Operation Strategy and Complications for Hilar Cholangiocarcinoma
Posted: April 9th, 2017, 10:00am EDT
Condition: Hilar Cholangiocarcinoma
Intervention:
Sponsor: Zhujiang Hospital
Not yet recruiting - verified February 2017 -
Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors
Posted: March 30th, 2017, 10:00am EDT
Condition: Neoplasms
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Anetumab ravtansine (BAY94-9343)
Sponsor: Bayer
Recruiting - verified June 2017 -
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
Posted: March 30th, 2017, 10:00am EDT
Conditions: Autoimmune Liver Disease; Autoimmune Hepatitis; Primary Sclerosing Cholangitis
Intervention:
Sponsor: Children's Hospital Medical Center, Cincinnati
Not yet recruiting - verified June 2017 -
Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma
Posted: March 26th, 2017, 10:00am EDT
Condition: Cholangitis
Intervention: Procedure: Injection of 37℃ contrast agent
Sponsor: Hepatopancreatobiliary Surgery Institute of Gansu Province
Not yet recruiting - verified April 2017 -
Enteral Nutrition After Pancreaticoduodenectomy
Posted: March 26th, 2017, 10:00am EDT
Conditions: Cancer of Pancreas; Cancer of Duodenum; Ampulla of Vater Cancer; Cholangiocarcinoma
Interventions: Other: Early enteral nutrition; Other: Saline; Device: nasojejunal tube insertion
Sponsor: Nanjing Medical University
Recruiting - verified August 2016 -
Best Biliary Drainage Option in Advanced Klatskin Tumor
Posted: March 25th, 2017, 10:00am EDT
Condition: Cholangitis
Interventions: Procedure: ERCP Drainage; Procedure: PTBD Drainage
Sponsor: Hepatopancreatobiliary Surgery Institute of Gansu Province
Recruiting - verified April 2017 -
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
Posted: March 22nd, 2017, 10:00am EDT
Conditions: Adenocarcinoma of the Gastroesophageal Junction; Colorectal Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Non-Resectable Cholangiocarcinoma; Non-Resectable Hepatocellular Carcinoma; Recurrent Cholangiocarcinoma; Recurrent Colorectal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Hepatocellular Carcinoma; Recurrent Pancreatic Carcinoma; Recurrent Small Intestinal Carcinoma; Small Intestinal Adenocarcinoma; Stage III Colorectal Cancer; Stage III Gastric Cancer; Stage III Hepatocellular Carcinoma; Stage III Pancreatic Cancer; Stage III Small Intestinal Cancer; Stage IIIA Colorectal Cancer; Stage IIIA Gastric Cancer; Stage IIIA Hepatocellular Carcinoma; Stage IIIA Small Intestinal Cancer; Stage IIIB Colorectal Cancer; Stage IIIB Gastric Cancer; Stage IIIB Hepatocellular Carcinoma; Stage IIIB Small Intestinal Cancer; Stage IIIC Gastric Cancer; Stage IV Colorectal Cancer; Stage IV Gastric Cancer; Stage IV Hepatocellular Carcinoma; Stage IV Pancreatic Cancer; Stage IV Small Intestinal Cancer; Stage IVA Colorectal Cancer; Stage IVA Hepatocellular Carcinoma; Stage IVA Pancreatic Cancer; Stage IVB Colorectal Cancer; Stage IVB Hepatocellular Carcinoma; Stage IVB Pancreatic Cancer; Unresectable Pancreatic Carcinoma; Unresectable Small Intestinal Carcinoma
Interventions: Drug: XL888; Biological: Pembrolizumab
Sponsors: Emory University; Merck Sharp & Dohme Corp.; Exelixis
Not yet recruiting - verified March 2017 -
Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma
Posted: March 13th, 2017, 10:00am EDT
Conditions: Bile Duct Cancer; Intrahepatic Cholangiocarcinoma
Interventions: Combination Product: Melphalan/HDS; Drug: Cisplatin and Gemcitabine
Sponsor: Delcath Systems Inc.
Not yet recruiting - verified March 2017 -
Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma
Posted: March 9th, 2017, 10:00am EST
Conditions: Cholangiocarcinoma; Biliary Tract Cancer; Adjuvant Chemotherapy; Capecitabine; Gemcitabine; Cisplatin
Interventions: Drug: Gemcitabine plus cisplatin; Drug: Capecitabine
Sponsor: Asan Medical Center
Not yet recruiting - verified March 2017 -
ncRNAs in Exosomes of Cholangiocarcinoma
Posted: March 8th, 2017, 10:00am EST
Conditions: Cholangiocarcinoma; Benign Biliary Stricture
Intervention:
Sponsor: The Second Hospital of Nanjing Medical University
Recruiting - verified March 2017 -
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
Posted: March 2nd, 2017, 10:00am EST
Condition: Advanced or Metastatic Solid Tumors
Interventions: Drug: ABBV-368; Drug: Nivolumab
Sponsor: AbbVie
Recruiting - verified May 2017 -
A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma
Posted: February 9th, 2017, 10:00am EST
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Carboplatin; Drug: Cisplatin; Drug: Gemcitabine
Sponsor: University of Louisville
Not yet recruiting - verified March 2017 -
Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies
Posted: January 26th, 2017, 10:00am EST
Conditions: Cholangiocarcinoma Non-resectable; Cholangiocarcinoma Metastatic; Cholangiocarcinoma of the Gallbladder; Cholangiocarcinoma Advanced
Interventions: Drug: nal-IRI; Drug: 5-FU; Drug: leucovorin
Sponsors: AIO-Studien-gGmbH; Shire
Not yet recruiting - verified June 2017 -
A Study of ABBV-181 in Participants With Advanced Solid Tumors
Posted: December 15th, 2016, 10:00am EST
Condition: Advanced Solid Tumors
Intervention: Drug: ABBV-181
Sponsor: AbbVie
Recruiting - verified May 2017 -
Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)
Posted: December 5th, 2016, 10:00am EST
Conditions: Advanced Cholangiocarcinoma; Metastatic Cholangiocarcinoma
Interventions: Drug: AG-120; Drug: AG-120 matched placebo
Sponsor: Agios Pharmaceuticals, Inc.
Recruiting - verified November 2016 -
Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy
Posted: October 4th, 2016, 10:00am EDT
Condition: Cholangiocarcinoma
Intervention: Drug: INCB054828
Sponsor: Incyte Corporation
Recruiting - verified May 2017 -
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
Posted: October 2nd, 2016, 10:00am EDT
Conditions: Gastrointestinal Cancer; Neuroendocrine Tumours; Malignant Female Reproductive System Neoplasm
Interventions: Drug: Ipilimumab; Drug: Nivolumab
Sponsors: Olivia Newton-John Cancer Research Institute; Bristol-Myers Squibb
Not yet recruiting - verified April 2017 -
Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery
Posted: August 23rd, 2016, 10:00am EDT
Conditions: Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Stage IV Liver Cancer; Stage IVA Liver Cancer; Stage IVB Liver Cancer; Vascular Thrombosis
Interventions: Procedure: Computed Tomography; Procedure: Single Photon Emission Computed Tomography; Radiation: Technetium Tc-99m Sulfur Colloid
Sponsors: University of Washington; National Cancer Institute (NCI)
Recruiting - verified March 2017 -
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Posted: June 29th, 2016, 10:00am EDT
Conditions: Liver Cell Caricinoma; Liver Cancer; Hapatocellular Carcinoma; Liver Neoplasms
Interventions: Drug: Durvalumab; Drug: Tremelimumab; Procedure: TACE; Procedure: RFA; Procedure: Cryoablation
Sponsor: National Cancer Institute (NCI)
Recruiting - verified May 25, 2017 -
Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Posted: June 22nd, 2016, 10:00am EDT
Conditions: Neoplasms; Pancreatic Neoplasms
Interventions: Drug: LMB-100; Drug: Nab-Paclitaxel
Sponsor: National Cancer Institute (NCI)
Recruiting - verified May 25, 2017 -
Superior Bilioenteric Anastomosis by Magnetic Compressive Technique
Posted: May 29th, 2016, 10:00am EDT
Conditions: Hilar Cholangiocarcinoma; Bile Duct Injury; Choledochal Cyst; Biliary Calculi
Interventions: Device: Magnetic Compressive Anastomosis; Procedure: Manual Anastomosis
Sponsors: First Affiliated Hospital Xi'an Jiaotong University; Shaanxi Provincial People's Hospital; Tang-Du Hospital; First Affiliated Hospital, Sun Yat-Sen University; First Affiliated Hospital of Xinjiang Medical University; General Hospital of Ningxia Medical University
Not yet recruiting - verified June 2017 -
Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers
Posted: February 24th, 2016, 10:00am EST
Conditions: Cholangiocarcinoma; Tumor; Klatskin Tumor
Intervention: Drug: Temoporfin
Sponsor: Chinese University of Hong Kong
Recruiting - verified April 2017 -
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Posted: December 15th, 2015, 10:00am EST
Conditions: Colorectal Adenocarcinoma; Cholangiocarcinoma; Pancreatic Adenocarcinoma; Hepatocellular Adenocarcinoma; Gastric Adenocarcinoma; Esophageal Adenocarcinoma
Intervention: Drug: ceritinib
Sponsors: Criterium, Inc.; University of Colorado, Denver; Novartis
Recruiting - verified April 2017 -
Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
Posted: October 12th, 2015, 10:00am EDT
Conditions: Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Sarcoma; Colorectal Neoplasms; Salivary Gland Neoplasms; Biliary Tract Neoplasms; Brain Neoplasm, Primary; Carcinoma, Ductal, Breast; Melanoma; Solid Tumors; Glioblastoma; Bile Duct Neoplasms; Astrocytoma; Head and Neck Squamous Cell Carcinoma; Pontine Glioma; Pancreatic Neoplasms; Ovarian Neoplasms; Carcinoma, Renal Cell; Cholangiocarcinoma; Carcinoma; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas
Intervention: Drug: LOXO-101
Sponsor: Loxo Oncology, Inc.
Recruiting - verified May 2017 -
Ramucirumab for Advanced Pre-Treated Biliary Cancers
Posted: August 5th, 2015, 10:00am EDT
Condition: Biliary Cancer
Intervention: Drug: Ramucirumab
Sponsors: M.D. Anderson Cancer Center; Eli Lilly and Company
Recruiting - verified June 2017 -
90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
Posted: July 29th, 2015, 10:00am EDT
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Device: SIR-Spheres microspheres (Yttrium-90 Microspheres); Drug: Gemcitabine; Drug: Cisplatin
Sponsor: Medical University of South Carolina
Recruiting - verified March 2017 -
Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma
Posted: March 10th, 2015, 10:00am EDT
Condition: Cholangiocarcinoma
Intervention: Drug: FOLFIRINOX
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Recruiting - verified June 2017 -
Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L
Posted: September 3rd, 2014, 10:00am EDT
Conditions: Hepatocellular Carcinoma; HCC; Liver Cancer
Interventions: Biological: hepcortespenlisimut-L; Biological: Placebo
Sponsor: Immunitor LLC
Recruiting - verified April 2017 -
A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer
Posted: September 3rd, 2014, 10:00am EDT
Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma
Intervention: Drug: BBI503
Sponsor: Boston Biomedical, Inc
Recruiting - verified March 2017 -
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Biliary Tract Cancer
Posted: June 18th, 2014, 10:00am EDT
Conditions: Cholangiocarcinoma; Gall Bladder Carcinoma
Interventions: Drug: Gemcitabine; Drug: Cisplatin; Other: Observation
Sponsors: Universitätsklinikum Hamburg-Eppendorf; Deutsche Krebshilfe e.V., Bonn (Germany); medac GmbH; Cancer Research UK; AGITG Australasian Gastro Intestinal Trials Group; KWF Kanker Bestrijding The Netherlands
Recruiting - verified March 2017 -
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
Posted: May 12th, 2014, 10:00am EDT
Condition: Advanced Cholangiocarcinoma
Intervention: Drug: BGJ398
Sponsor: Novartis Pharmaceuticals
Recruiting - verified May 2017 -
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
Posted: July 31st, 2013, 10:00am EDT
Conditions: Colorectal Neoplasms; Gastric Neoplasms; Cholangiocarcinoma; Bile Duct Cancer; Pancreas Cancer
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting - verified April 25, 2017 -
Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).
Posted: February 16th, 2013, 10:00am EST
Condition: Intrahepatic Cholangiocellular Carcinoma
Interventions: Procedure: DEB TACE; Procedure: SIRT
Sponsor: Johannes Gutenberg University Mainz
Recruiting - verified May 2017 -
CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
Posted: January 10th, 2013, 10:00am EST
Conditions: Adult Primary Cholangiocellular Carcinoma; Advanced Adult Primary Liver Cancer; Cholangiocarcinoma of the Extrahepatic Bile Duct; Cholangiocarcinoma of the Gallbladder; Localized Unresectable Adult Primary Liver Cancer; Metastatic Extrahepatic Bile Duct Cancer; Recurrent Adult Primary Liver Cancer; Recurrent Extrahepatic Bile Duct Cancer; Unresectable Extrahepatic Bile Duct Cancer
Intervention: Drug: 6,8-bis(benzylthio)octanoic acid
Sponsors: Wake Forest University Health Sciences; National Cancer Institute (NCI)
Recruiting - verified March 2017 -
Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin
Posted: July 17th, 2012, 10:00am EDT
Condition: Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Device: LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo; Drug: Gem-Cis or Gem-Carbo
Sponsors: Robert C. Martin; University of Louisville
Recruiting - verified August 2016 -
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
Posted: July 16th, 2012, 10:00am EDT
Conditions: Acinar Cell Adenocarcinoma of the Pancreas; Adenocarcinoma of the Gallbladder; Adenocarcinoma of Unknown Primary; Adult Primary Cholangiocellular Carcinoma; Advanced Adult Primary Liver Cancer; Cholangiocarcinoma of the Extrahepatic Bile Duct; Cholangiocarcinoma of the Gallbladder; Diffuse Adenocarcinoma of the Stomach; Duct Cell Adenocarcinoma of the Pancreas; Intestinal Adenocarcinoma of the Stomach; Localized Unresectable Adult Primary Liver Cancer; Metastatic Carcinoma of Unknown Primary; Metastatic Extrahepatic Bile Duct Cancer; Mixed Adenocarcinoma of the Stomach; Mucinous Adenocarcinoma of the Colon; Mucinous Adenocarcinoma of the Rectum; Newly Diagnosed Carcinoma of Unknown Primary; Signet Ring Adenocarcinoma of the Colon; Signet Ring Adenocarcinoma of the Rectum; Stage III Pancreatic Cancer; Stage IIIA Colon Cancer; Stage IIIA Gallbladder Cancer; Stage IIIA Gastric Cancer; Stage IIIA Rectal Cancer; Stage IIIB Colon Cancer; Stage IIIB Gallbladder Cancer; Stage IIIB Gastric Cancer; Stage IIIB Rectal Cancer; Stage IIIC Colon Cancer; Stage IIIC Gastric Cancer; Stage IIIC Rectal Cancer; Stage IV Gastric Cancer; Stage IV Pancreatic Cancer; Stage IVA Colon Cancer; Stage IVA Gallbladder Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Gallbladder Cancer; Stage IVB Rectal Cancer; Unresectable Extrahepatic Bile Duct Cancer
Interventions: Drug: oxaliplatin; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: fluorouracil; Other: laboratory biomarker analysis
Sponsors: University of Chicago; National Cancer Institute (NCI)
Recruiting - verified April 2017 -
A Study of LY2801653 in Advanced Cancer
Posted: January 26th, 2011, 10:00am EST
Condition: Cancer
Interventions: Drug: LY2801653; Drug: Cetuximab; Drug: Cisplatin; Drug: Gemcitabine; Drug: Ramucirumab
Sponsor: Eli Lilly and Company
Recruiting - verified March 2017